MetaCap

Telomir Pharmaceuticals Inc. (TELO)

NASDAQ: TELOHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.364-0.0758 (-17.24%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

TELO stock chart

Technical analysis

Key statistics

All statistics
Market cap
$26.82M
EPS (TTM)
-$0.96
52-week range
0.353 – 1.58
Day range
0.3578 – 0.4371
Volume / Avg
255.91K / 126.14K
Beta
—

52-week range

$0.353$1.58

TELO stock today

On Nov 20, TELO ended the session at $0.364, shedding $0.0758 (17.24%), versus the S&P 500's 3.70% decline. Volume was 2.0x the average at 255.91K shares, a sign of unusually heavy trading. At this level, TELO sits near the bottom of its 52-week range of $0.353 to $1.58: 77.0% below the high, set on Oct 6, 2026 and 3.1% above the low.

TELO is down 72.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 71.6%. Telomir Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$0.96), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Telomir Pharmaceuticals

Company profile

Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria. The company was formerly known as Metallo Therapies Inc.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Erez Aminov
Headquarters
Miami, FL
IPO year
2024

Financial highlights

Full financials

Telomir Pharmaceuticals reported a net loss of $10.4 million, compared with a loss of $16.5 million a year earlier. Diluted earnings per share came in at -$0.33.

Telomir Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022
Revenue————
Growth————
Net income$-10.41M$-16.53M$-13.07M$-854.15K
EPS (diluted)$-0.33$-0.56$0.48$-0.03

Analyst forecast

Forecast

Consensus (1 analysts)

none

Avg. price target

$4.00+998.90%

  • Strong buy 1
  • Buy 0
  • Hold 0
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-0.01 vs —

TELO news

All TELO news

Telomir Pharmaceuticals peers

Health Care sector
TELO peer companies
CompanyPrice% ChgMarket capCompare
NSRXNasus Pharma Ltd.2.29-10.20%$26.82Mvs TELO
BCTXBriaCell Therapeutics Corp.3.06-3.32%$26.72Mvs TELO
EDSAEdesa Biotech Inc.2.00-8.05%$27.02Mvs TELO
PMNProMIS Neurosciences Inc.3.16-1.56%$28.43Mvs TELO
AYTUAytu BioPharma Inc.2.660.00%$28.91Mvs TELO
ATHEAlterity Therapeutics Limited ADR1.52-8.16%$29.02Mvs TELO
RNTXRein Therapeutics Inc.0.3369-8.38%$29.06Mvs TELO
NNVCNanoViricides Inc.1.14-2.56%$29.13Mvs TELO

Indexes, lists and sector

Telomir Pharmaceuticals stock FAQ

What is Telomir Pharmaceuticals's stock price today?

TELO last traded at $0.364 as of Nov 20, 4:00 PM EST, down 17.24% on the day. Prices are delayed at least 15 minutes.

Who is Telomir Pharmaceuticals's CEO?

Mr. Erez Aminov is the chief executive officer of Telomir Pharmaceuticals Inc..

What is the TELO 52-week high?

The 52-week high for TELO is $1.58 and the 52-week low is $0.353. The stock is currently 77.0% below its high.

Compare TELO